Connection

WILLEM OVERWIJK to Melanoma, Experimental

This is a "connection" page, showing publications WILLEM OVERWIJK has written about Melanoma, Experimental.
Connection Strength

2.699
  1. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat Commun. 2017 11 13; 8(1):1447.
    View in: PubMed
    Score: 0.495
  2. Persistent antigen at vaccination sites induces tumor-specific CD8? T cell sequestration, dysfunction and deletion. Nat Med. 2013 Apr; 19(4):465-72.
    View in: PubMed
    Score: 0.358
  3. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003 Aug 18; 198(4):569-80.
    View in: PubMed
    Score: 0.185
  4. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade. Front Immunol. 2022; 13:794684.
    View in: PubMed
    Score: 0.170
  5. B16 as a mouse model for human melanoma. Curr Protoc Immunol. 2001 May; Chapter 20:Unit 20.1.
    View in: PubMed
    Score: 0.157
  6. IL-1a Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol. 2021 04 15; 206(8):1966-1975.
    View in: PubMed
    Score: 0.156
  7. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):2982-7.
    View in: PubMed
    Score: 0.136
  8. Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma. J Immunother. 2017 01; 40(1):11-20.
    View in: PubMed
    Score: 0.117
  9. Temporally Programmed CD8a+ DC Activation Enhances Combination Cancer Immunotherapy. Cell Rep. 2016 12 06; 17(10):2503-2511.
    View in: PubMed
    Score: 0.116
  10. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol. 2014 Nov 01; 193(9):4722-31.
    View in: PubMed
    Score: 0.100
  11. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J Immunother. 2012 Apr; 35(3):276-82.
    View in: PubMed
    Score: 0.084
  12. Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity. PLoS One. 2011; 6(8):e22939.
    View in: PubMed
    Score: 0.080
  13. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res. 2010 Nov 15; 16(22):5458-68.
    View in: PubMed
    Score: 0.076
  14. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res. 2010 May 01; 16(9):2550-61.
    View in: PubMed
    Score: 0.073
  15. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008 Mar; 118(3):1165-75.
    View in: PubMed
    Score: 0.063
  16. T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother. 2008 Jan; 31(1):1-6.
    View in: PubMed
    Score: 0.062
  17. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005 Mar 01; 174(5):2591-601.
    View in: PubMed
    Score: 0.051
  18. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med. 2001 Aug 20; 194(4):481-9.
    View in: PubMed
    Score: 0.040
  19. An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci U S A. 2000 May 09; 97(10):5492-7.
    View in: PubMed
    Score: 0.037
  20. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res. 2000 Jan 15; 60(2):253-8.
    View in: PubMed
    Score: 0.036
  21. Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter. Clin Cancer Res. 2017 Oct 15; 23(20):6151-6164.
    View in: PubMed
    Score: 0.030
  22. Mouse model for pre-clinical study of human cancer immunotherapy. Curr Protoc Immunol. 2015 Feb 02; 108:20.1.1-20.1.43.
    View in: PubMed
    Score: 0.026
  23. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol. 2012 Jun 01; 188(11):5365-76.
    View in: PubMed
    Score: 0.021
  24. Induction of TLR4-dependent CD8+ T cell immunity by murine ?-defensin2 fusion protein vaccines. Vaccine. 2011 Apr 18; 29(18):3476-82.
    View in: PubMed
    Score: 0.019
  25. Immunization against endogenous retroviral tumor-associated antigens. Cancer Res. 2001 Nov 01; 61(21):7920-4.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.